<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3364">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02148601</url>
  </required_header>
  <id_info>
    <org_study_id>A1192013</org_study_id>
    <nct_id>NCT02148601</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection</brief_title>
  <official_title>Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection: an Open-label Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the recent past, a deep change in the epidemiology of C. difficile infection has
      occurred, with a rise in its frequency, severity, and mortality. Both the refractoriness of
      the infection to standard therapy and its probability of recurrence have also increased,
      representing a main clinical issue. Fecal microbiota transplantation (FMT)  refers to the
      introduction of a liquid filtrate of stools from a healthy donor into the gastrointestinal
      tract of a patient for the treatment of specific diseases. FMT has shown outstanding results
      in the treatment of recurrent C. difficile infection. It can be performed through various
      routes: nasogastric or nasojejunal tube, upper endoscopy, retention enema, colonoscopy. In a
      recent systematic review of studies using FMT for the treatment of recurrent C. difficile
      infection, Cammarota et al. observed that lower gastrointestinal route (colonoscopy, enema)
      led to the achievement of higher eradication rates than upper delivery (gastroscopy,
      naso-gastric or naso-jejunal tube) (81-86% vs 84-93%, respectively). In a randomized
      clinical trial, Van Nood et al. showed the efficacy of FMT by nasojejunal tube in recurrent
      C. difficile infection. Up to now, data on FMT by lower route come out only by case series
      and case reports.

      The investigators' aim is to compare the efficacy of colonoscopic FMT and  standard
      antibiotic therapy for the treatment of C. difficile infection in a randomized clinical
      trial
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the recent past, a deep change in the epidemiology of C. difficile infection has
      occurred, with a rise in its frequency, severity, and mortality. Both the refractoriness of
      the infection to standard therapy and its probability of recurrence have also increased,
      representing a main clinical issue. Fecal microbiota transplantation (FMT)  refers to the
      introduction of a liquid filtrate of stools from a healthy donor into the gastrointestinal
      tract of a patient for the treatment of specific diseases. FMT has shown outstanding results
      in the treatment of recurrent C. difficile infection. It can be performed through various
      routes: nasogastric or nasojejunal tube, upper endoscopy, retention enema, colonoscopy. In a
      recent systematic review of studies using FMT for the treatment of recurrent C. difficile
      infection, Cammarota et al. observed that lower gastrointestinal route (colonoscopy, enema)
      led to the achievement of higher eradication rates than upper delivery (gastroscopy,
      naso-gastric or naso-jejunal tube) (81-86% vs 84-93%, respectively). In a randomized
      clinical trial, Van Nood et al. showed the efficacy of FMT by nasojejunal tube in recurrent
      C. difficile infection. Up to now, data on FMT by lower route come out only by case series
      and case reports.

      The investigators' aim is to compare the efficacy of colonoscopic FMT and  standard
      antibiotic therapy for the treatment of C. difficile infection in an open-label randomized
      clinical trial The investigators' trial should confirm the clinical results obtained by Van
      Nood et al. by using a colonoscopy approach.

      The investigators' study is an open-label randomized controlled trial, enrolling patients
      with recurrent C. difficile infection, who are candidates for further antibiotic treatment
      in accordance with guidelines. Recurrent C. difficile infection is meant as the reappearance
      of clinical symptoms and positivity of C. difficile toxin test within 8 weeks after the end
      of the previous therapy. Patients' stool will be screened for detection of parasites and
      enteric bacterial pathogens to exclude other infective pathogens. Patients with severe
      clinical features (sepsis, severe dehydration, major co-morbidities), former colectomy,
      high-risk of endoscopic complications, inflammatory bowel diseases (IBD), irritable bowel
      syndrome (IBS), viral hepatitis, AIDS or syphilis will be excluded.

      Patients will be instructed and invited to signal recurrent symptoms and diarrhea after
      treatment. Monthly clinical and lab checks will be performed for a period of six months
      after the treatment.

      Treatment procedures:

      All patients will start therapy with vancomycin for four days before of stratification, with
      random allocation (1 to 1) to one of the two treatment schemes: 1) FMT, with the infusion in
      the cecum - through the biopsy channel - of 60-120 gr (depending on production) of donated
      feces, obtained from the donor within 6 hours from transplantation, and manually homogenized
      in 100/200 ml of physiological solution; or 2) standard vancomycin-based therapy according
      to the international recommendations. Colonoscopy will be performed by an expert
      endoscopist, with mucosal biopsy (when possible) for histology examination. Patients
      allocated to FMT arm will undergo preparation for colonoscopy  (four liters of a solution
      with saline laxatives). All patient will be instructed on hygiene rules to be followed at
      the patient's domicile to avoid re-infections at home. Stool donors should preferably be
      patient's relatives or intimates, must not have taken antibiotics in the last 6 months,
      should not present significant intestinal symptoms of other intestinal diseases and must
      result negative at the serum screening for viral hepatitis, AIDS or syphilis. Their stool
      will be tested for C. difficile, enteric bacteria, intestinal protozoa and helminthes
      pathogens.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Disappearance of clinical symptoms linked to C. difficile infection</measure>
    <time_frame>10 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Negativization of C. difficile toxin in stools</measure>
    <time_frame>10 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Recurrent C. Difficile Infection.</condition>
  <arm_group>
    <arm_group_label>Fecal Microbiota Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal microbiota transplantation from healthy donors will be infused by colonoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Antibiotic Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard antibiotic therapy according to European Guidelines (vancomycin and metronidazole) will be administered to the patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fecal Microbiota Transplantation</intervention_name>
    <arm_group_label>Fecal Microbiota Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Antibiotic Therapy</intervention_name>
    <arm_group_label>Standard Antibiotic Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin (before randomization)</intervention_name>
    <description>Vancomycin will be administered in all patients for 5 days before randomization. Then, patients will be randomized in FMT Group or Standard Antibiotic therapy Group. Patients in the FMT Group will stop vancomycin 24 hours before the fecal microbiota transplantation. Patients in the Standard Antibiotic Therapy Group will continue vancomycin.</description>
    <arm_group_label>Fecal Microbiota Transplantation</arm_group_label>
    <arm_group_label>Standard Antibiotic Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic recurrent C. difficile infection identified by positivity of C. difficile
             toxin in stools (ELISA)

          -  Possibility to undergo standard antimicrobial therapy for recurrent C. difficile
             infection

          -  Approval of informed consent

          -  Possibility to undergo protocol diagnostic and therapeutic procedures

          -  Stool negativity for parasites

          -  Stool negativity for Salmonella spp., Shigella spp., Yersinia enterocolitica,
             Campylobacter, Streptococcus agalactiae, Staphylococcus aureus, enteropathogenic
             Escherichia coli and other microorganisms except for C. difficile

          -  Blood negativity for: Hepatitis A virus-Immunoglobulin M, HBsAg, Anti-Hepatitis C
             Virus, Anti-Human Immunodeficiency Virus1-2, venereal disease reaction level  (VDRL).

        Exclusion Criteria:

          -  Subjects &lt;18 years old

          -  Main comorbidities

          -  Prior colectomy

          -  Negativity of C. difficile toxin in stools

          -  High risk of post-colonoscopy complications

          -  Other main gastrointestinal diseases (es. Crohn's disease or ulcerative colitis)

          -  Stool positivity for parasites

          -  Stool positivity for Salmonella spp., Shigella spp., Yersinia enterocolitica,
             Campylobacter, Streptococcus agalactiae, Staphylococcus aureus, enteropathogenic
             Escherichia coli and other microorganisms except for C. difficile

          -  Blood positivity for: Hepatitis A virus-Immunoglobulin M, HBsAg, Anti-Hepatitis C
             Virus, Anti-Human Immunodeficiency Virus1-2, venereal disease reaction level  (VDRL).

          -  Pregnancy or breastfeeding.

          -  Inability to follow protocol procedures
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Giovanni Cammarota, Professor</last_name>
    <phone>+390630155948</phone>
    <email>gcammarota@rm.unicatt.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Catholic University of Sacred Heart - &quot;A. Gemelli&quot; University Hospital</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Cammarota, Professor</last_name>
      <phone>+390630155948</phone>
      <email>gcammarota@rm.unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Giovanni Cammarota, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gianluca Ianiro, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luca Masucci, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Cammarota G, Ianiro G, Bibb√≤ S, Gasbarrini A. Gut microbiota modulation: probiotics, antibiotics or fecal microbiota transplantation? Intern Emerg Med. 2014 Mar 25. [Epub ahead of print] PubMed</citation>
    <PMID>24664520</PMID>
  </reference>
  <reference>
    <citation>Cammarota G, Ianiro G, Gasbarrini A, Masucci L, Sanguinetti M. Faecal transplantation for Clostridium difficile infection. Three cases treated in Italy. Dig Liver Dis. 2014 May;46(5):475. doi: 10.1016/j.dld.2013.12.011. Epub 2014 Jan 20. PubMed</citation>
    <PMID>24457126</PMID>
  </reference>
  <reference>
    <citation>Cammarota G, Ianiro G, Gasbarrini A. Fecal Microbiota Transplantation for the Treatment of Clostridium difficile Infection: A Systematic Review. J Clin Gastroenterol. 2014 Jan 16. [Epub ahead of print] PubMed</citation>
    <PMID>24440934</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>May 23, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University of the Sacred Heart</investigator_affiliation>
    <investigator_full_name>Giovanni Cammarota</investigator_full_name>
    <investigator_title>Prof. Giovanni Cammarota</investigator_title>
  </responsible_party>
  <keyword>Fecal microbiota transplantation</keyword>
  <keyword>Recurrent C. difficile infection</keyword>
  <keyword>Colonoscopy</keyword>
  <keyword>Randomized clinical trial</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
